


# Phase 2 Trial in Platinum-Resistant Ovarian Cancer (PROC) Resulted in a Statistically Significant Improvement in Progression-Free Survival (PFS)



## USE OF PROCEEDS


- ▶ Adaptive trial: Ph2 into pivotal (US + EU/MENA)
- ▶ Triple-negative breast cancer (TNBC): Ph2a: **Complete**; Ph2b (US + EU/MENA)
- ▶ Collaborations & market evaluation for exit (IPO/reverse merger/sale)

## ▶ NOVEL DRUG




- DNA plasmid encoding human protein “p62”
- Pipeline of future generations of products

## ▶ PROC \$1.9B (2032); TNBC \$1.5B (2030) – just 1-year median survival overall




## ▶ MULTIPLE MECHANISMS OF ACTION

- Changes tumor microenvironment making tumors more sensitive to chemo-, immuno-, and radiotherapies
- Induces stem cells and immune cells to secrete anti-inflammatory signals acting remotely
- Also, induces direct anti-cancer immune response



## ▶ PROC PROGRESSION-FREE SURVIVAL (20+20 patients)

Gemcitabine (median 2.7 months) versus Gemcitabine + Elenagen (median 7.2 months)



## PATENTS IN 20+ COUNTRIES FOR

- Treatment of cancer
- Treatment or diseases of chronic inflammation (Australia, Belarus, Belgium, Canada, Chile, France, Germany, Hong Kong, Ireland, India, Italy Japan, Lichtenstein, Luxembourg, Mexico, Netherlands, Russia, Singapore, South Korea, Spain, Switzerland, UK, USA)

• +3 pending; +2 to be submitted in 2025 (see [curelaboncoology.com/ip/](http://curelaboncoology.com/ip/))

## ▶ OC OVERALL-FREE SURVIVAL (20+20 patients)

Gemcitabine (median 12.5 months) versus Gemcitabine + Elenagen (median 24.5 months)

## ▶ RECENT DEAL

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE®

- \$10.1B; treats a subset of the market based on a biomarker
- ~5% complete response; ~40% partial response rate
- Approved on PFS endpoint

# CURELAB TEAM



## ALEX SHNEIDER, PhD — FOUNDER & CEO

25+ years in biotech; patents in over 20 countries; scientific paper held #1 position as the most read paper by Faculty 1000; editorial board member for journal *International Review of Immunology*.



## CHARLES LEGG — COO

25+ years in biotech. Background in Rare/Orphan diseases, Gene Therapies (Cell/LVV & AAV) Oncology, Regulated Diagnostics, AI & NLP. Two successful IPOs, multiple product launches.



## AUBREY GALLOWAY, MD — CHIEF MEDICAL OFFICER

The Seymour Cohn Professor at NYU Langone. Distinguished leader in medicine. >230 articles, co-inventor, participated in numerous successful clinical trials.



## GABRIEL LEVIN, MD — DIRECTOR OF ONCOLOGY

Gynecologic Oncologist at McGill University Health Centre, Montréal, Canada. >300 publications, participated in numerous Phase I, II, III clinical trials advancing treatment options in gynecologic cancers.



## ILYA LAPSHIN, JD — GENERAL COUNSEL

18 years in a large New York law firm & two Massachusetts-based boutique firms. Worked with startups to large corporate clients. Graduate of Boston University Law School.



## VLAD GABAI, VP RESEARCH

30+ years in biotech. Focus on R&D of anti-cancer drugs from bench to bedside. >80 papers, >4,000 references. Previous: Boston University & Boston Biomedical Research Institute.



## RICARDA CRAMER, MBA — DIRECTOR BD, EU



## JIHAD FAKHREDDINE — DIRECTOR BD, GCC

## Development timeline

